title: Translating the Science of Aging into Therapeutic Interventions.
abstract: Life and health span have been extended in experimental animals using drugs that are potentially translatable into humans. Considerable effort is needed beyond the usual steps in drug development to devise the models, and realistic preclinical and clinical trial strategies are required to advance these agents into clinical application. It will be important to focus on subjects who already have symptoms or are at imminent risk of developing disorders related to fundamental aging processes, to use short-term, clinically relevant outcomes, as opposed to long-term outcomes, such as health span or life span, and to validate endpoint measures so they are acceptable to regulatory agencies. Funding is a roadblock, as is shortage of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and investigational new drug clinical trials. Strategies for developing a path from the bench to the bedside are reviewed for interventions that target fundamental aging mechanisms.
authors.affiliation: Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota 55905.
authors.forename: James L
authors.initials: JL
authors.lastname: Kirkland
mesh_terms: D000375:Aging / Q000502:physiology; D000818:Animals; D015415:Biomarkers / Q000032:analysis; D035843:Biomedical Research; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D015415:Biomarkers